|

HMPL-A830 in Solid Tumors

RECRUITINGPhase 1/2Sponsored by Hutchmed
Actively Recruiting
PhasePhase 1/2
SponsorHutchmed
Started2026-09-24
Est. completion2029-05-23
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations6 sites

Summary

This is a first-in-human (FIH), multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors\*, who are refractory or progressed on/after available standard treatment. The study will be conducted in 2 parts: Dose Escalation (Part A, Phase I), approximately 57 participants will be enrolled. Dose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Understood this study and are able to voluntarily sign the informed consent form (ICF);
2. Male or Female, Age ≥ 18 years;
3. Histological confirmed, unresectable, advanced or metastatic solid tumor
4. Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1
5. Life expectancy ≥ 12 weeks
6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1

Exclusion Criteria:

1. Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug
2. Major surgery within 28 days prior to the first dose of study drug
3. Active infection requiring systemic treatment
4. History of inflammatory gastrointestinal diseases
5. Known hypersensitivity to any component of HMPL-A830
6. Pregnant (positive pregnancy test) or lactating;

Conditions2

CancerSolid Tumor, Adult

Interventions1

Locations6 sites

University of California Irvine Medical Center
Orange, California, 92868
Zhaohui Arter714-456-7890zarter@hs.uci.edu
BRCR Global
Coral Springs, Florida, 33065
Sumit Sawhney561-447-0614Ssawhney.md@brcrglobal.com
Florida Clinical Trials Group
Plantation, Florida, 33322
Chintan Gandhi772-297-3057cgandhi@floridactg.com
START New Jersey
East Brunswick, New Jersey, 08816
Bruno Fang732-390-7725Bruno.fang@startresearch.com
SCRI Oncology Partners
Melissa Johnson615-329-7640mjohnson@tnonc.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.